Perspective Therapeutics (CATX) Common Equity (2011 - 2026)

Perspective Therapeutics has disclosed Common Equity across 16 years of filings, most recently posting $347.4 million for Q1 2026.

• Common Equity for Q1 2026 came in at $347.4 million, up 22.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $347.4 million (up 22.06% YoY), and the FY2025 annual result was $207.0 million, down 28.77% from the prior year.
• Common Equity came in at $347.4 million for Q1 2026 at Perspective Therapeutics, up from $207.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $347.4 million in Q1 2026 to a low of $54.6 million in Q4 2022.
• The 5-year median for Common Equity is $207.0 million (2025), against an average of $186.7 million.
• Across the five-year window, Common Equity surged 286.63% in 2024 and fell 28.77% in 2025, its largest moves.
• Perspective Therapeutics' Common Equity stood at $54.6 million in 2022, then surged by 37.58% to $75.2 million in 2023, then soared by 286.63% to $290.7 million in 2024, then dropped by 28.77% to $207.0 million in 2025, then soared by 67.82% to $347.4 million in 2026.
• The last three Common Equity figures came in at $347.4 million (Q1 2026), $207.0 million (Q4 2025), and $242.2 million (Q3 2025), per Business Quant data.